TAXUS® Express²® Coronary Stent System

Product Information

A Proven Stent
The Express² Stent platform offers excellent deliverability and conformability.

• Excellent deliverability allows for treatment of a variety of patient and lesion types.¹
• Excellent conformability allows the stent to mold to the natural contours of the vessel wall.¹
• Broad working range facilitates precise deployment and sizing flexibility, making it easy to achieve full stent apposition.¹

A Reliable Polymer
The TAXUS stent uses Translute™ Polymer, a proprietary polymer carrier technology, to control drug release.

• The durable Translute Polymer protects the drug and maintains coating integrity during preparation, delivery, and stent expansion.
• The polymer controls the release of paclitaxel, which may allow for consistent drug release and more uniform drug distribution.²

An Effective Drug
The unique properties of paclitaxel may contribute to the efficacy of the TAXUS Stent.

• Paclitaxel's multi-functional effects, stabilize microtubules and inhibit activities that contribute to restenosis.³
• Paclitaxel is highly lipophilic, which may contribute to more uniform drug distribution.⁴
• At the dose used in the TAXUS Stent, paclitaxel does not impede the natural healing process.⁵

Device Illustration

Additional Information

Sources:
¹Boston Scientific Bench Tests (data on file).
²"Paclitaxel release from inert polymer material-coated stents curtails coronary in-stent restenosis in pigs" - Rogers et al. - Circulation. 2000; 102 (18 Supplement):II566-II567.
³"The Multifunctional Effects of Paclitaxel on the Neointimal Cascade: A Close Look at the Role of Microtubules" - Boston Scientific (2002).
⁴"Arterial Paclitaxel Distribution and Deposition" - Circulation Research. 2000; 86:879-884.
⁵"Paclitaxel Inhibits Arterial Smooth Muscle Proliferation and Migration In Vitro and In Vivo Using Local Drug Delivery" - Axel et al. - Circulation. 1997; 96:636-645.